SANTA CRUZ BIOTECHNOLOGY, INC.

PDE3B (D-17): sc-11837

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Phosphodiesterases (PDE, also designated cyclic nucleotide phosphodiesterase) are important for the downregulation of the intracellular level of the second messenger cyclic adenosine monophosphate (cAMP) by hydrolyzing cAMP to 5'AMP. Phosphodiesterase type 3 isoforms, PDE3A and 3B, are expressed primarily in cardiovascular tissue and adipose tissue, respectively. PDE3A, is a 120 kDa protein found in myocardium and platelets and PDE3B is a 135 kDa protein found in lymphocytes. The 57 kDa PDE7A1 (HCP1) isozyme and the 50 kDa PDE7A2 proteins, alternate splice products of PDE7A, are highly expressed in skeletal muscle. PDE7B has a molecular mass of 50.1 kDa and is most highly expressed in pancreas. The PDE family contains proteins that serve tissue-specific roles in regulation of lipolysis, glycogenolysis, myocardial contractility, and smooth muscle relaxation.

REFERENCES

1. Bloom, T.J. and Beavo, J.A. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93: 14188-14192.
2. Han, P., Zhu, X., and Michaeli, T. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. 272: 16152-16157.
3. Fisher, D.A., et al. 1998. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 246: 570-577.
4. Liu, H. and Maurice, D.H. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125: 1501-1510.
5. Gantner, F., et al. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br. J. Pharmacol. 123: 1031-1038.

SOURCE

PDE3B (D-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of PDE3B of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-11837 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

APPLICATIONS

PDE3B (D-17) is recommended for detection of PDE3B of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of PDE3B: 135 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.